Worthwhile Clinical Trials
Welcome,         Profile    Billing    Logout  
 6 Trials 
17 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Dheda, Keertan
NCT05436795: A Randomized Controlled Trial of a Digital, Self-testing Strategy for COVID-19 Infection in South Africa.

Recruiting
1/2
600
RoW
Abbott Panbio rapid antigen self-tests, COVIDSmart CARE! app
McGill University Health Centre/Research Institute of the McGill University Health Centre, University of Cape Town Lung Institute
COVID-19
12/23
03/24
Epi-TB, NCT06135818: Same Day Diagnosis of Extrapulmonary TB (TB Serositis and TB Meningitis).

Recruiting
N/A
2160
RoW
IRISA-TB
University of Cape Town, European Union, Zambart, Biomedical Research and Training Institute, Leiden University Medical Center, University of Cape Town Lung Institute
Tuberculosis, Extrapulmonary
05/25
05/26
ISIT-TB, NCT04995406: Validating the Use of Blood Transcriptomic Signatures for the Diagnosis of Active Pulmonary Tuberculosis

Completed
N/A
722
RoW
ISIT-TB prototype
BioMérieux
TUBERCULOSIS, PULMONARY
05/23
12/23
XACT-3, NCT04303104: Xpert Active Case-finding Trial 3

Active, not recruiting
N/A
3394
RoW
GeneXpert Edge, GeneXpert Ultra
University of Cape Town, Zambart (University of Zambia), Zambia, Instituto Nacional de Saúde, Mozambique, Biomedical Research and Training Institute, Zimbabwe, Radboud University Medical Center, London School of Hygiene and Tropical Medicine, University of Cape Town Lung Institute
Tuberculosis
08/24
12/25
NCT05220163: Evaluating the Impact of Computer-assisted X-ray Diagnosis and Other Triage Tools to Optimise Xpert Orientated Community-based Active Case Finding for TB and COVID-19

Recruiting
N/A
26200
RoW
CAD, CAD4TB and/or other AI/CAD software, Xpert, GeneXpert System
University of Cape Town, European and Developing Countries Clinical Trials Partnership (EDCTP), Zambart, Biomedical Research and Training Institute, Ospedale San Raffaele, Radboud University Medical Center, Foundation for Innovative New Diagnostics, Switzerland, University of Stellenbosch
Tuberculosis, COVID-19, HIV Infections
01/25
03/25
T3-RCT, NCT05007795: Test to Treat TB: Impact of Sputum Sequencing-guided Individualised Therapy on Outcomes in Drug-resistant Tuberculosis

Not yet recruiting
N/A
280
RoW
Targeted sequencing using the GenoScreen Deeplex assay
University of Cape Town, University of Stellenbosch, Ospedale San Raffaele, Stichting Katholieke Universiteit, University of Cape Town Lung Institute
Tuberculosis, Multidrug-Resistant
08/26
07/27
Kwiecień, Tomasz
NCT04469686 / 2019-003596-19: Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories

Completed
3
200
US
Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator, Twice Daily - Active, Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator, Once Daily - Active, Twice daily placebo suppository administered with Sephure applicator, Twice Daily - Placebo
Cristcot LLC, Cristcot HCA LLC
Ulcerative Proctitis
07/24
09/24
Venter, Gustav
NCT05368285 / 2021-006413-11: A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Active, not recruiting
2
208
Europe, US, RoW
barzolvolimab, CDX-0159, Matching Placebo
Celldex Therapeutics
Chronic Spontaneous Urticaria
09/23
03/25
CDX0159-07, NCT05405660 / 2021-006447-95: A Study of CDX-0159 in Patients With Chronic Inducible Urticaria

Active, not recruiting
2
196
Europe, US, RoW
barzolvolimab, CDX-0159, Matching Placebo
Celldex Therapeutics, Celldex Therapeutics, Inc.
Chronic Inducible Urticaria
06/24
09/25
Taljaard, Jessica
NCT05368285 / 2021-006413-11: A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Active, not recruiting
2
208
Europe, US, RoW
barzolvolimab, CDX-0159, Matching Placebo
Celldex Therapeutics
Chronic Spontaneous Urticaria
09/23
03/25
CDX0159-07, NCT05405660 / 2021-006447-95: A Study of CDX-0159 in Patients With Chronic Inducible Urticaria

Active, not recruiting
2
196
Europe, US, RoW
barzolvolimab, CDX-0159, Matching Placebo
Celldex Therapeutics, Celldex Therapeutics, Inc.
Chronic Inducible Urticaria
06/24
09/25
Hussen, Nazreen Jeewa
ASUCOV, NCT05639192: Asunercept for the Treatment of Patients With Moderate to Severe COVID-19 Disease

Terminated
3
34
Europe, RoW
Asunercept, Placebo
Apogenix GmbH
COVID-19
08/23
08/23
NCT04469686 / 2019-003596-19: Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories

Completed
3
200
US
Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator, Twice Daily - Active, Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator, Once Daily - Active, Twice daily placebo suppository administered with Sephure applicator, Twice Daily - Placebo
Cristcot LLC, Cristcot HCA LLC
Ulcerative Proctitis
07/24
09/24
NECTAR, NCT05593770 / 2022-000715-31: International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response

Terminated
2/3
28
Europe, RoW
Fostamatinib, Placebo
NEAT ID Foundation, National Institutes of Health (NIH)
COVID-19, SARS-CoV2 Infection, Coronavirus Infection
12/23
12/23
NCT05212818 / 2021-000748-24: Evaluate the Efficacy and Safety of TF0023 in Treatments for COVID-19 in Hospitalized Adults

Terminated
2
19
US, RoW
TF0023, IP, Active drug
Techfields Inc
COVID-19 Pneumonia
02/23
03/23
COMET-PACE, NCT05124210 / 2021-003717-18: Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19

Terminated
2
8
US
Sotrovimab
GlaxoSmithKline, Vir Biotechnology, Inc.
COVID-19
06/23
06/23
Caballero, Abherdyn
NCT04469686 / 2019-003596-19: Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories

Completed
3
200
US
Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator, Twice Daily - Active, Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator, Once Daily - Active, Twice daily placebo suppository administered with Sephure applicator, Twice Daily - Placebo
Cristcot LLC, Cristcot HCA LLC
Ulcerative Proctitis
07/24
09/24

Download Options